logo
‘Cosmic joust': Astronomers catch first sight of two dueling galaxies

‘Cosmic joust': Astronomers catch first sight of two dueling galaxies

CNN23-05-2025

(CNN) — Astronomers have for the first time spotted two galaxies in the throes of a deep-space 'duel.'
Using combined observations from ground-based telescopes over nearly four years, the researchers saw the distant galactic neighbors charging toward each other at more than 1.1 million miles per hour (1.8 million kilometers per hour). One repeatedly wielded its intense beams of radiation at the other, dispersing gas clouds and weakening its opponent's ability to form new stars.
'That's why we call it a 'cosmic joust,'' said Pasquier Noterdaeme, a researcher for the Paris Institute of Astrophysics and the French-Chilean Laboratory for Astronomy in Chile who was part of the team that made the discovery.
What Noterdaeme and his colleagues spied was a distant snapshot of the two galaxies in the process of merging into one large galaxy 11 billion light-years away. The findings, described in a study published Wednesday in the journal Nature, provide a rare look into earlier times in the universe, when star formation and galaxy mergers were more common.
Working with the European Southern Observatory's Very Large Telescope (VLT) and the Atacama Large Millimeter/submillimeter Array (ALMA) in Chile, the researchers found that the 'attacking' galaxy's piercing radiation comes from within its bright core, a quasar, powered by a supermassive black hole.
The intense gravitational influence of a black hole draws matter toward it in such an energetic way that dust and gas heat up to millions of degrees and become luminous, according to NASA. These luminous materials spiral around the black hole before entering, forming what's called an 'accretion disk,' and jets of energetic matter beam out away from the center.
Each blast of the quasar's ultraviolet waves are about a thousand times stronger than the radiation of our Milky Way, causing hydrogen molecules from some of the 'victim' galaxy's star-forming nurseries to split and disperse, according to the study.
Stars form when large clumps of gas and dust reach a critical mass and collapse under their own gravity. However, researchers observed that after being dispersed by the radiation, the clouds were not dense or large enough to create new stars.
As additional material from the victim galaxy is drawn within reach of the supermassive black hole, it fuels the quasar with more energy. Quasars have been known to essentially 'switch off' from time to time, said study coauthor Sergei Balashev, a researcher at the Ioffe Institute in St. Petersburg, Russia, which could give molecular clouds the opportunity to reform.
'It's really the first time that we can see the radiative effect of a quasar on the molecular gas of a nearby galaxy,' Balashev said. Until now, this effect had only been theorized but not confirmed through direct observation.
Scientists initially wanted to observe this particular quasar more closely because of its unique features among thousands of low-resolution spectra, which are like fingerprints for distant celestial objects, offering clues about composition, temperature and activity within them.
'It's really (like) finding a needle in a haystack,' Balashev said. However, the light from quasars is so powerful that it often outshines their own host galaxies, making it difficult to observe other galaxies close by, according to Noterdaeme, the study's co-lead author.
Highly dynamic, luminous quasars are rare, according to NASA. Only about 1,000 of these objects are known to exist in the early days of the universe, Anniek Gloudemans, a postdoctoral research fellow at the National Science Foundation's NOIRLab, previously told CNN via email.
'At first, we just knew there was some molecular gas between the (attacking galaxy's) quasar and us. It's only after, when we started to look with bigger telescopes, that we detected there were actually two galaxies,' Noterdaeme said.
While the dueling pair appears to be overlapping in the low-resolution spectra, the high-resolution imaging capabilities of ALMA revealed the galaxies are actually separated by thousands of light-years. Using the Very Large Telescope, the researchers were able to study the density and distance of the gas affected by the quasar's radiation.
Since the light from these objects came from billions of light-years away in the early universe, it's possible the two galaxies have already merged by now, but there is no way to be sure, Balashev said.
Scientists believe quasars and galaxy mergers used to be far more common earlier in the universe's lifetime, said Dong-Woo Kim, an astrophysicist with the Harvard and Smithsonian Center for Astrophysics who was not involved in the research.
Galaxies merge when they are pulled toward each other by gravity, and the universe used to be more densely packed together. Over time, the universe has expanded, and more galaxies have combined into larger ones, Kim said.
Noterdaeme said that 10 billion years ago was an interesting time in the universe, adding that astronomers call this period when stars formed at a rapid rate the 'noon of the universe.'
Though less frequent, galaxy mergers are still happening all the time, Kim said. Even our own Milky Way is expected to merge with the Andromeda galaxy in a few billion years, but the study team isn't certain yet whether the 'cosmic joust' phenomenon is a common feature when two galaxies collide and form a larger one.
'It's an exciting field to study,' Kim said. 'Research like this can teach us more about the birth of new galaxies and observe how they evolve over time.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Software suggests Rubin Observatory will discover millions of solar system objects in its first year
Software suggests Rubin Observatory will discover millions of solar system objects in its first year

Geek Wire

time4 hours ago

  • Geek Wire

Software suggests Rubin Observatory will discover millions of solar system objects in its first year

A new type of computer simulation predicts that the Vera C. Rubin Observatory in Chile will discover 2.85 million previously undetected objects in the solar system in its first year of operation, with millions more to be spotted in the years that follow. The discovery campaign, which is due to begin in earnest later this year, should expand the known population of small bodies in the solar system by a factor of four to nine, said University of Washington astronomer Mario Juric, a member of the research team behind the open-source Sorcha simulation software. 'With this data, we'll be able to update the textbooks of solar system formation and vastly improve our ability to spot — and potentially deflect — the asteroids that could threaten Earth,' Juric said today in a news release. Several studies describing the software and the predictions have been accepted for publication by The Astronomical Journal. The project was led by researchers from Queen's University Belfast in collaboration with colleagues from UW, the Harvard & Smithsonian Center for Astrophysics and the University of Illinois at Urbana-Champaign. The software's name is derived from the Gaelic word for 'brightness.' Sorcha starts with the Rubin Observatory's planned observing schedule, factors in how the telescope makes its observations, and matches up those capabilities with the best model for the current state of the solar system and its reservoirs of small bodies such as asteroids. 'Accurate simulation software like Sorcha is critical,' said Queen's University astronomer Meg Schwamb, who led the research team. 'It tells us what Rubin will discover and lets us know how to interpret it. Our knowledge of what objects fill Earth's solar system is about to expand exponentially and rapidly.' The software suggests that, over the course of a 10-year campaign known as the Legacy Survey of Space and Time, Rubin will map more than 5 million main-belt asteroids, 127,000 near-Earth objects, 109,000 Trojan asteroids that share Jupiter's orbit, 37,000 trans-Neptunian objects and about 2,000 orbit-crossing objects known as Centaurs. Jake Kurlander, a UW doctoral student who's the principal author of one of the studies, said Rubin's observations should double the number of known asteroids in the solar system in less than a year. 'Rubin's unparalleled combination of breadth and depth make it a uniquely effective discovery machine,' he said. The observatory's Simonyi Survey Telescope — which is named after the family of Seattle software pioneer Charles Simonyi — is designed to observe small bodies multiple times using different optical filters, revealing their surface colors. Past solar system surveys typically made observations using a single filter. 'With the LSST catalog of solar system objects, our work shows that it will be like going from black-and-white television to brilliant color,' said Joe Murtagh, a doctoral student at Queen's University. The Rubin Observatory team has already started making preliminary observations and will share some of those early images at a First Look event on June 23. Check out for more information about the Sorcha simulation software. The Rubin Observatory is funded by the National Science Foundation and the U.S. Department of Energy's Office of Science, with additional support from other organizations and private contributors including Charles Simonyi and Bill Gates. The research papers relating to the Sorcha project include:

Pierre Nora, 93, Who Probed Role of Memory in Writing of History, Dies
Pierre Nora, 93, Who Probed Role of Memory in Writing of History, Dies

New York Times

time10 hours ago

  • New York Times

Pierre Nora, 93, Who Probed Role of Memory in Writing of History, Dies

Pierre Nora, a French scholar whose ideas about the role of memory and identity in the writing of history gained prominence both in France and abroad, and who became a kingpin in his country's intellectual community through his great influence over publishing, died on Monday in Paris. He was 93. His death, in a hospital, was confirmed by his son, Elphège Nora, who said the cause was multiple organ failures. Mr. Nora's major contribution to historiography was the concept of 'lieux de mémoire' ('sites of memory'), a term he coined to describe elements of the past that a community chooses to remember and which become symbolic of a shared identity. Examples would be Joan of Arc, the national anthem 'La Marseillaise' and the rooster — 'le coq gaulois' — as an unofficial icon of France. This concept has been highly influential in the field of memory studies, shaping discussions elsewhere in Europe, the United States and Asia about how memory functions in societies, particularly in how nations remember and forget. Mr. Nora wrote during a period when French scholars were increasingly interested in the roles of language, symbols and discourse in forging social realities. His approach to history seemed to complement then-current theories like Claude Lévi-Strauss's structuralism and Jacques Derrida's deconstructionism. Mr. Nora's approach also sparked debate and criticism, particularly regarding the potential for 'sites of memory' to oversimplify or sanitize history, obscuring more complex or contentious aspects of the past. Want all of The Times? Subscribe.

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Associated Press

time17 hours ago

  • Associated Press

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion. Alyssa Johnsen, MD, PhD Global Therapeutic Area Head, Immunology and Oncology Development 'Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation thatcouldimprove and streamline the treatment process for both patients and providers. We are pleased to share thesedata, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forwardtopotentiallybringing this formulation and administrationoptionto the multiple myeloma community.' The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection. The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections' enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort. The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any regulatory authority. IRAKLIA phase 3 study IRAKLIA is a global, randomized, open-label, pivotal phase 3 non-inferiority study comparing Sarclisa SC administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone (Pd) in adult patients with R/R MM who have received at least one prior line of treatment. At the data cut-off of November 6, 2024, and a median follow-up of 12 months, the study demonstrated: Primary endpoints Secondary endpoints The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a notably lower rate of systemic IRs. No new safety concerns were observed, except for low-grade local injection site reactions (ISRs) associated with SC administration that occurred with a low incidence (0.4%, n=19/5,145 injections). Nearly all ISRs were grade 1, except for one episode of grade 2. Xavier Leleu, MD, PhD Head of the Department of Hematology and Myeloma Clinic at the Hôpital La Mileterie and study investigator 'Results from the IRAKLIA phase 3 study represent a potentially transformational advancement in the administration of multiple myeloma treatment. These data not only establish non-inferiority between Sarclisa administered both subcutaneously and intravenously across several key endpoints but reinforce the positive impact that this on-body injector could have on the patient treatment experience, as demonstrated by patient satisfaction scores.' In addition to the oral presentation at ASCO, the full data were simultaneously published in the Journal of Clinical Oncology. IZALCO phase 2 study In addition to the IRAKLIA phase 3 study, Sanofi also presented new data from the randomized, sequential, open-label, IZALCO phase 2 study evaluating the efficacy and safety of Sarclisa SC administered via manual push or an OBI, in combination with carfilzomib and dexamethasone (Kd) in adult patients with R/R MM who have received one to three prior lines of therapy. At a median follow-up of 10.1 months, the study demonstrated: The overall safety profile of Sarclisa SC-Kd observed in this study was consistent with the established safety profile of Sarclisa IV-Kd, with no new safety concerns observed. Advancing patient and provider-centric innovation in MM While SC administration is currently available for certain MM treatment regimens through a manual injection, administering large-volume medicines manually can present significant challenges, including a labor-intensive process for nurses, risk of strain and needlestick injuries, and potential need for larger needles that may compromise patient comfort and increase anxiety. Mehul Desai, PharmD, MBA Vice President, Medical Affairs, Enable Injections 'We believe multiple myeloma patients deserve a more convenient and comfortable treatment experience and recognize the crucial role providers play in delivering that care. Through our collaboration with Sanofi, we've aspired to advance an on-body injector that could transform the treatment experience for patients and providers alike. The results from the IRAKLIA and IZALCO studies represent a significant step toward our ambition and validate the potential of the on-body injector to deliver the same high standard of efficacy established with intravenous Sarclisa.' In addition to IRAKLIA and IZALCO, Sanofi is also evaluating Sarclisa SC administration via an OBI in the front-line treatment setting. The ISASOCUT phase 2 study conducted by the University of Poitiers, is evaluating Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) in adult patients with newly diagnosed MM (NDMM) not eligible for autologous stem-cell transplant (ASCT), while the German-speaking Myeloma Multicenter Group (GMMG)-HD8 phase 3 study, conducted in collaboration with the GMMG and the German Multiple Myeloma Study Group Consortium (DSMM), is evaluating Sarclisa SC-VRd induction in NDMM patients who are eligible for ASCT. In addition, results from the IZALCO, IRAKLIA and ISASOCUT studies will be presented at the European Hematology Association Congress later this month. The IRAKLIA abstract was also hand-selected to be included in the 2025 Best of ASCO program, held later in the summer of 2025, following the ASCO Annual Meeting. The data from these studies, collectively, will form the basis for global regulatory submissions. Sarclisa administered subcutaneously via the on-body injector or manual administration is investigational and has not been approved for any use by any regulatory authority. The safety and efficacy of this formulation and delivery method have not been established. About the IRAKLIA and IZALCO studies IRAKLIA is a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of Sarclisa SC formulation administered at a fixed dose SC via an OBI versus weight-based dosed Sarclisa IV in combination with Pd in adult patients with R/R MM who have received at least one prior line of therapy. The co-primary outcomes being assessed are ORR, defined as the proportion of patients with stringent CR, CR, VGPR, and partial response (PR) according to the 2016 IMWG criteria assessed by Independent Review Committee (IRC), and observed C trough at steady state (pre-dose at C6D1), defined as observed Sarclisa plasma concentrations. IZALCO is a two-part, randomized, sequential, open-label, phase 2 study evaluating the efficacy and safety of Sarclisa SC formulation administered SC via manual push or an OBI in adult patients with R/R MM who have received one to three prior lines of therapy. The primary objective is ORR, as assessed by IRC. The secondary objective is patient preference for the OBI versus manual administration of Sarclisa SC. About Enable Injections Based in the US (Cincinnati, OH), Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of enFuse. enFuse is an innovative wearable drug delivery platform that is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit About Sarclisa Sarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, UK, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media Relations Sandrine Guendoul | +33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Léo Le Bourhis | +33 6 75 06 43 81 | [email protected] Victor Rouault | +33 6 70 93 71 40 | [email protected] Timothy Gilbert | +1 516 521 2929 | [email protected] Investor Relations Thomas Kudsk Larsen |+44 7545 513 693 | [email protected] Alizé Kaisserian | +33 6 47 04 12 11 | [email protected] Felix Lauscher | +1 908 612 7239 | [email protected] Keita Browne | +1 781 249 1766 | [email protected] Nathalie Pham | +33 7 85 93 30 17 | [email protected] Tarik Elgoutni | +1 617 710 3587 | [email protected] Thibaud Châtelet | +33 6 80 80 89 90 | [email protected] Yun Li | +33 6 84 00 90 72 | [email protected] Sanofi forward-looking statements All trademarks mentioned in this press release are the property of the Sanofi group with the exception of enFuse. Attachment

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store